Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
Cancer Cell · 2025-10 · 43 (10) · 1958-1967.e2
DOI: 10.1016/j.ccell.2025.09.004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Feng Wang und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Sun Yat-sen University, Sun Yat-sen University Cancer Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China;…
- West China Hospital of Sichuan University, Chengdu, China.
- Shanxi Cancer Hospital, Taiyuan, China.
- Guangxi Medical University Cancer Hospital, Nanning, China.
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
- Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Förderung
- National Natural Science Foundation of China
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center
- Innovent Biologics
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Wang, F., Chen, G., Qiu, M., Ma, J., Mo, X., Liu, H., Li, Y., Ding, P., Wan, X., Hu, Y., Huang, X., Jiang, W., Wu, X., Luo, J., Zhou, Y., Li, L., Sun, Y., Wang, Q., Wang, N., …, & Xu, R. H. (2025). Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study. Cancer Cell, 43(10), 1958-1967.e2. https://doi.org/10.1016/j.ccell.2025.09.004
Vancouver
Wang F, Chen G, Qiu M, Ma J, Mo X, Liu H, et al. Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study. Cancer Cell. 2025;43(10):1958-1967.e2. doi:10.1016/j.ccell.2025.09.004
BibTeX
@article{Wang2025,
author = {Wang, Feng and Chen, Gong and Qiu, Meng and Ma, Jinfeng and Mo, Xianwei and Liu, Haiyi and Li, Yongqiang and Ding, Peirong and Wan, Xiangbin and Hu, Yingbin and Huang, Xiwen and Jiang, Weiqin and Wu, Xiaojun and Luo, Jia and Zhou, Yanbing and Li, Leping and Sun, Yanlai and Wang, Quan and Wang, Nanya and Jiang, Wu and Yuan, Weitang and Li, Liren and Liu, Linlin and Yuan, Xianglin and Wang, Guihua and Song, Zhangfa and Liu, Heli and Ge, Jie and Wang, Yaxu and Zhao, Peng and Li, Taiyuan and You, Jun and Tang, Jianqiang and Du, Xiaobo and Lin, Junzhong and Zhang, Rongxin and Fu, Zan and Xu, Jianmin and Zhong, Haijun and Kang, Liang and Deng, Yanhong and Lu, Xiaoxiao and Guo, Qun and Zhou, Hui and Xu, Rui-Hua},
title = {Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {10},
pages = {1958--1967.e2},
doi = {10.1016/j.ccell.2025.09.004}
}
EUVIMED